Compile Data Set for Download or QSAR
Report error Found 272 Enz. Inhib. hit(s) with all data for entry = 694
TargetCytochrome P450 11B2, mitochondrial(Human)
Viamet Pharmaceuticals (Bermuda)

US Patent
LigandPNGBDBM287626(US10085984, Example 4 | US11040034, Ex. No. 4)
Affinity DataIC50: 100nMAssay Description:V79-4 cells expressing recombinant andrenodoxin and andrenodoxin reductase with either recombinant human CYP11B2 or CYP11B1 were prepared according t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/17/2019
Entry Details
Go to US Patent

TargetCytochrome P450 11B2, mitochondrial(Human)
Viamet Pharmaceuticals (Bermuda)

US Patent
LigandPNGBDBM287628(US10085984, Example 6 | US11040034, Ex. No. 6)
Affinity DataIC50: 100nMAssay Description:V79-4 cells expressing recombinant andrenodoxin and andrenodoxin reductase with either recombinant human CYP11B2 or CYP11B1 were prepared according t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/17/2019
Entry Details
Go to US Patent

TargetCytochrome P450 11B2, mitochondrial(Human)
Viamet Pharmaceuticals (Bermuda)

US Patent
LigandPNGBDBM287629(US10085984, Example 7 | US11040034, Ex. No. 7)
Affinity DataIC50: 100nMAssay Description:V79-4 cells expressing recombinant andrenodoxin and andrenodoxin reductase with either recombinant human CYP11B2 or CYP11B1 were prepared according t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/17/2019
Entry Details
Go to US Patent

TargetCytochrome P450 11B2, mitochondrial(Human)
Viamet Pharmaceuticals (Bermuda)

US Patent
LigandPNGBDBM287632(US10085984, Example 10 | US11040034, Ex. No. 10)
Affinity DataIC50: 100nMAssay Description:V79-4 cells expressing recombinant andrenodoxin and andrenodoxin reductase with either recombinant human CYP11B2 or CYP11B1 were prepared according t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/17/2019
Entry Details
Go to US Patent

TargetCytochrome P450 11B2, mitochondrial(Human)
Viamet Pharmaceuticals (Bermuda)

US Patent
LigandPNGBDBM287633(US10085984, Example 11 | US11040034, Ex. No. 11)
Affinity DataIC50: 100nMAssay Description:V79-4 cells expressing recombinant andrenodoxin and andrenodoxin reductase with either recombinant human CYP11B2 or CYP11B1 were prepared according t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/17/2019
Entry Details
Go to US Patent

TargetCytochrome P450 11B2, mitochondrial(Human)
Viamet Pharmaceuticals (Bermuda)

US Patent
LigandPNGBDBM287634(US10085984, Example 12 | US11040034, Ex. No. 12)
Affinity DataIC50: 100nMAssay Description:V79-4 cells expressing recombinant andrenodoxin and andrenodoxin reductase with either recombinant human CYP11B2 or CYP11B1 were prepared according t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/17/2019
Entry Details
Go to US Patent

TargetCytochrome P450 11B2, mitochondrial(Human)
Viamet Pharmaceuticals (Bermuda)

US Patent
LigandPNGBDBM287636(US10085984, Example 14 | US11040034, Ex. No. 14)
Affinity DataIC50: 100nMAssay Description:V79-4 cells expressing recombinant andrenodoxin and andrenodoxin reductase with either recombinant human CYP11B2 or CYP11B1 were prepared according t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/17/2019
Entry Details
Go to US Patent

TargetCytochrome P450 11B2, mitochondrial(Human)
Viamet Pharmaceuticals (Bermuda)

US Patent
LigandPNGBDBM287637(US10085984, Example 15 | US11040034, Ex. No. 15)
Affinity DataIC50: 100nMAssay Description:V79-4 cells expressing recombinant andrenodoxin and andrenodoxin reductase with either recombinant human CYP11B2 or CYP11B1 were prepared according t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/17/2019
Entry Details
Go to US Patent

TargetCytochrome P450 11B2, mitochondrial(Human)
Viamet Pharmaceuticals (Bermuda)

US Patent
LigandPNGBDBM287640(US10085984, Example 18 | US11040034, Ex. No. 18)
Affinity DataIC50: 100nMAssay Description:V79-4 cells expressing recombinant andrenodoxin and andrenodoxin reductase with either recombinant human CYP11B2 or CYP11B1 were prepared according t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/17/2019
Entry Details
Go to US Patent

TargetCytochrome P450 11B2, mitochondrial(Human)
Viamet Pharmaceuticals (Bermuda)

US Patent
LigandPNGBDBM287641(US10085984, Example 19 | US11040034, Ex. No. 19)
Affinity DataIC50: 100nMAssay Description:V79-4 cells expressing recombinant andrenodoxin and andrenodoxin reductase with either recombinant human CYP11B2 or CYP11B1 were prepared according t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/17/2019
Entry Details
Go to US Patent

TargetCytochrome P450 11B2, mitochondrial(Human)
Viamet Pharmaceuticals (Bermuda)

US Patent
LigandPNGBDBM287643(US10085984, Example 21 | US11040034, Ex. No. 21)
Affinity DataIC50: 100nMAssay Description:V79-4 cells expressing recombinant andrenodoxin and andrenodoxin reductase with either recombinant human CYP11B2 or CYP11B1 were prepared according t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/17/2019
Entry Details
Go to US Patent

TargetCytochrome P450 11B2, mitochondrial(Human)
Viamet Pharmaceuticals (Bermuda)

US Patent
LigandPNGBDBM287644(US10085984, Example 22 | US11040034, Ex. No. 22)
Affinity DataIC50: 100nMAssay Description:V79-4 cells expressing recombinant andrenodoxin and andrenodoxin reductase with either recombinant human CYP11B2 or CYP11B1 were prepared according t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/17/2019
Entry Details
Go to US Patent

TargetCytochrome P450 11B2, mitochondrial(Human)
Viamet Pharmaceuticals (Bermuda)

US Patent
LigandPNGBDBM287645(US10085984, Example 23 | US11040034, Ex. No. 23)
Affinity DataIC50: 100nMAssay Description:V79-4 cells expressing recombinant andrenodoxin and andrenodoxin reductase with either recombinant human CYP11B2 or CYP11B1 were prepared according t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/17/2019
Entry Details
Go to US Patent

TargetCytochrome P450 11B2, mitochondrial(Human)
Viamet Pharmaceuticals (Bermuda)

US Patent
LigandPNGBDBM287646(US10085984, Example 24 | US11040034, Ex. No. 24)
Affinity DataIC50: 100nMAssay Description:V79-4 cells expressing recombinant andrenodoxin and andrenodoxin reductase with either recombinant human CYP11B2 or CYP11B1 were prepared according t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/17/2019
Entry Details
Go to US Patent

TargetCytochrome P450 11B2, mitochondrial(Human)
Viamet Pharmaceuticals (Bermuda)

US Patent
LigandPNGBDBM287647(US10085984, Example 25 | US11040034, Ex. No. 25)
Affinity DataIC50: 100nMAssay Description:V79-4 cells expressing recombinant andrenodoxin and andrenodoxin reductase with either recombinant human CYP11B2 or CYP11B1 were prepared according t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/17/2019
Entry Details
Go to US Patent

TargetCytochrome P450 11B2, mitochondrial(Human)
Viamet Pharmaceuticals (Bermuda)

US Patent
LigandPNGBDBM287648(US10085984, Example 26 | US11040034, Ex. No. 26)
Affinity DataIC50: 100nMAssay Description:V79-4 cells expressing recombinant andrenodoxin and andrenodoxin reductase with either recombinant human CYP11B2 or CYP11B1 were prepared according t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/17/2019
Entry Details
Go to US Patent

TargetCytochrome P450 11B2, mitochondrial(Human)
Viamet Pharmaceuticals (Bermuda)

US Patent
LigandPNGBDBM287649(US10085984, Example 27 | US11040034, Ex. No. 27)
Affinity DataIC50: 100nMAssay Description:V79-4 cells expressing recombinant andrenodoxin and andrenodoxin reductase with either recombinant human CYP11B2 or CYP11B1 were prepared according t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/17/2019
Entry Details
Go to US Patent

TargetCytochrome P450 11B2, mitochondrial(Human)
Viamet Pharmaceuticals (Bermuda)

US Patent
LigandPNGBDBM287650(US10085984, Example 28 | US11040034, Ex. No. 28)
Affinity DataIC50: 100nMAssay Description:V79-4 cells expressing recombinant andrenodoxin and andrenodoxin reductase with either recombinant human CYP11B2 or CYP11B1 were prepared according t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/17/2019
Entry Details
Go to US Patent

TargetCytochrome P450 11B2, mitochondrial(Human)
Viamet Pharmaceuticals (Bermuda)

US Patent
LigandPNGBDBM287651(US10085984, Example 29 | US11040034, Ex. No. 29)
Affinity DataIC50: 100nMAssay Description:V79-4 cells expressing recombinant andrenodoxin and andrenodoxin reductase with either recombinant human CYP11B2 or CYP11B1 were prepared according t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/17/2019
Entry Details
Go to US Patent

TargetCytochrome P450 11B2, mitochondrial(Human)
Viamet Pharmaceuticals (Bermuda)

US Patent
LigandPNGBDBM287652(US10085984, Example 30 | US11040034, Ex. No. 30)
Affinity DataIC50: 100nMAssay Description:V79-4 cells expressing recombinant andrenodoxin and andrenodoxin reductase with either recombinant human CYP11B2 or CYP11B1 were prepared according t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/17/2019
Entry Details
Go to US Patent

TargetCytochrome P450 11B2, mitochondrial(Human)
Viamet Pharmaceuticals (Bermuda)

US Patent
LigandPNGBDBM287653(US10085984, Example 31 | US11040034, Ex. No. 31)
Affinity DataIC50: 100nMAssay Description:V79-4 cells expressing recombinant andrenodoxin and andrenodoxin reductase with either recombinant human CYP11B2 or CYP11B1 were prepared according t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/17/2019
Entry Details
Go to US Patent

TargetCytochrome P450 11B2, mitochondrial(Human)
Viamet Pharmaceuticals (Bermuda)

US Patent
LigandPNGBDBM287654(US10085984, Example 32 | US11040034, Ex. No. 32)
Affinity DataIC50: 100nMAssay Description:V79-4 cells expressing recombinant andrenodoxin and andrenodoxin reductase with either recombinant human CYP11B2 or CYP11B1 were prepared according t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/17/2019
Entry Details
Go to US Patent

TargetCytochrome P450 11B2, mitochondrial(Human)
Viamet Pharmaceuticals (Bermuda)

US Patent
LigandPNGBDBM287655(US10085984, Example 33 | US11040034, Ex. No. 33)
Affinity DataIC50: 100nMAssay Description:V79-4 cells expressing recombinant andrenodoxin and andrenodoxin reductase with either recombinant human CYP11B2 or CYP11B1 were prepared according t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/17/2019
Entry Details
Go to US Patent

TargetCytochrome P450 11B2, mitochondrial(Human)
Viamet Pharmaceuticals (Bermuda)

US Patent
LigandPNGBDBM287656(US10085984, Example 34 | US11040034, Ex. No. 34)
Affinity DataIC50: 100nMAssay Description:V79-4 cells expressing recombinant andrenodoxin and andrenodoxin reductase with either recombinant human CYP11B2 or CYP11B1 were prepared according t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/17/2019
Entry Details
Go to US Patent

TargetCytochrome P450 11B2, mitochondrial(Human)
Viamet Pharmaceuticals (Bermuda)

US Patent
LigandPNGBDBM287657(US10085984, Example 35 | US11040034, Ex. No. 35)
Affinity DataIC50: 100nMAssay Description:V79-4 cells expressing recombinant andrenodoxin and andrenodoxin reductase with either recombinant human CYP11B2 or CYP11B1 were prepared according t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/17/2019
Entry Details
Go to US Patent

TargetCytochrome P450 11B2, mitochondrial(Human)
Viamet Pharmaceuticals (Bermuda)

US Patent
LigandPNGBDBM287658(US10085984, Example 36 | US11040034, Ex. No. 36)
Affinity DataIC50: 100nMAssay Description:V79-4 cells expressing recombinant andrenodoxin and andrenodoxin reductase with either recombinant human CYP11B2 or CYP11B1 were prepared according t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/17/2019
Entry Details
Go to US Patent

TargetCytochrome P450 11B2, mitochondrial(Human)
Viamet Pharmaceuticals (Bermuda)

US Patent
LigandPNGBDBM287659(US10085984, Example 37 | US11040034, Ex. No. 37)
Affinity DataIC50: 100nMAssay Description:V79-4 cells expressing recombinant andrenodoxin and andrenodoxin reductase with either recombinant human CYP11B2 or CYP11B1 were prepared according t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/17/2019
Entry Details
Go to US Patent

TargetCytochrome P450 11B2, mitochondrial(Human)
Viamet Pharmaceuticals (Bermuda)

US Patent
LigandPNGBDBM287660(US10085984, Example 38 | US11040034, Ex. No. 38)
Affinity DataIC50: 100nMAssay Description:V79-4 cells expressing recombinant andrenodoxin and andrenodoxin reductase with either recombinant human CYP11B2 or CYP11B1 were prepared according t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/17/2019
Entry Details
Go to US Patent

TargetCytochrome P450 11B2, mitochondrial(Human)
Viamet Pharmaceuticals (Bermuda)

US Patent
LigandPNGBDBM287661(US10085984, Example 39)
Affinity DataIC50: 100nMAssay Description:V79-4 cells expressing recombinant andrenodoxin and andrenodoxin reductase with either recombinant human CYP11B2 or CYP11B1 were prepared according t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/17/2019
Entry Details
Go to US Patent

TargetCytochrome P450 11B1, mitochondrial(Human)
Viamet Pharmaceuticals (Bermuda)

US Patent
LigandPNGBDBM287661(US10085984, Example 39)
Affinity DataIC50: 100nMAssay Description:V79-4 cells expressing recombinant andrenodoxin and andrenodoxin reductase with either recombinant human CYP11B2 or CYP11B1 were prepared according t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/17/2019
Entry Details
Go to US Patent

TargetCytochrome P450 11B2, mitochondrial(Human)
Viamet Pharmaceuticals (Bermuda)

US Patent
LigandPNGBDBM287662(US10085984, Example 40 | US11040034, Ex. No. 40)
Affinity DataIC50: 100nMAssay Description:V79-4 cells expressing recombinant andrenodoxin and andrenodoxin reductase with either recombinant human CYP11B2 or CYP11B1 were prepared according t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/17/2019
Entry Details
Go to US Patent

TargetCytochrome P450 11B2, mitochondrial(Human)
Viamet Pharmaceuticals (Bermuda)

US Patent
LigandPNGBDBM287663(US10085984, Example 41 | US11040034, Ex. No. 41)
Affinity DataIC50: 100nMAssay Description:V79-4 cells expressing recombinant andrenodoxin and andrenodoxin reductase with either recombinant human CYP11B2 or CYP11B1 were prepared according t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/17/2019
Entry Details
Go to US Patent

TargetCytochrome P450 11B2, mitochondrial(Human)
Viamet Pharmaceuticals (Bermuda)

US Patent
LigandPNGBDBM287664(US10085984, Example 42 | US11040034, Ex. No. 42)
Affinity DataIC50: 100nMAssay Description:V79-4 cells expressing recombinant andrenodoxin and andrenodoxin reductase with either recombinant human CYP11B2 or CYP11B1 were prepared according t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/17/2019
Entry Details
Go to US Patent

TargetCytochrome P450 11B2, mitochondrial(Human)
Viamet Pharmaceuticals (Bermuda)

US Patent
LigandPNGBDBM287665(US10085984, Example 43 | US11040034, Ex. No. 43)
Affinity DataIC50: 100nMAssay Description:V79-4 cells expressing recombinant andrenodoxin and andrenodoxin reductase with either recombinant human CYP11B2 or CYP11B1 were prepared according t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/17/2019
Entry Details
Go to US Patent

TargetCytochrome P450 11B2, mitochondrial(Human)
Viamet Pharmaceuticals (Bermuda)

US Patent
LigandPNGBDBM287666(US10085984, Example 44 | US11040034, Ex. No. 44)
Affinity DataIC50: 100nMAssay Description:V79-4 cells expressing recombinant andrenodoxin and andrenodoxin reductase with either recombinant human CYP11B2 or CYP11B1 were prepared according t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/17/2019
Entry Details
Go to US Patent

TargetCytochrome P450 11B2, mitochondrial(Human)
Viamet Pharmaceuticals (Bermuda)

US Patent
LigandPNGBDBM287667(US10085984, Example 45 | US11040034, Ex. No. 45)
Affinity DataIC50: 100nMAssay Description:V79-4 cells expressing recombinant andrenodoxin and andrenodoxin reductase with either recombinant human CYP11B2 or CYP11B1 were prepared according t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/17/2019
Entry Details
Go to US Patent

TargetCytochrome P450 11B2, mitochondrial(Human)
Viamet Pharmaceuticals (Bermuda)

US Patent
LigandPNGBDBM287668(US10085984, Example 46 | US11040034, Ex. No. 46)
Affinity DataIC50: 100nMAssay Description:V79-4 cells expressing recombinant andrenodoxin and andrenodoxin reductase with either recombinant human CYP11B2 or CYP11B1 were prepared according t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/17/2019
Entry Details
Go to US Patent

TargetCytochrome P450 11B2, mitochondrial(Human)
Viamet Pharmaceuticals (Bermuda)

US Patent
LigandPNGBDBM287669(US10085984, Example 47 | US11040034, Ex. No. 47)
Affinity DataIC50: 100nMAssay Description:V79-4 cells expressing recombinant andrenodoxin and andrenodoxin reductase with either recombinant human CYP11B2 or CYP11B1 were prepared according t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/17/2019
Entry Details
Go to US Patent

TargetCytochrome P450 11B2, mitochondrial(Human)
Viamet Pharmaceuticals (Bermuda)

US Patent
LigandPNGBDBM287671(US10085984, Example 49 | US11040034, Ex. No. 49)
Affinity DataIC50: 100nMAssay Description:V79-4 cells expressing recombinant andrenodoxin and andrenodoxin reductase with either recombinant human CYP11B2 or CYP11B1 were prepared according t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/17/2019
Entry Details
Go to US Patent

TargetCytochrome P450 11B2, mitochondrial(Human)
Viamet Pharmaceuticals (Bermuda)

US Patent
LigandPNGBDBM287673(US10085984, Example 51 | US11040034, Ex. No. 51)
Affinity DataIC50: 100nMAssay Description:V79-4 cells expressing recombinant andrenodoxin and andrenodoxin reductase with either recombinant human CYP11B2 or CYP11B1 were prepared according t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/17/2019
Entry Details
Go to US Patent

TargetCytochrome P450 11B2, mitochondrial(Human)
Viamet Pharmaceuticals (Bermuda)

US Patent
LigandPNGBDBM287675(US10085984, Example 53)
Affinity DataIC50: 100nMAssay Description:V79-4 cells expressing recombinant andrenodoxin and andrenodoxin reductase with either recombinant human CYP11B2 or CYP11B1 were prepared according t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/17/2019
Entry Details
Go to US Patent

TargetCytochrome P450 11B2, mitochondrial(Human)
Viamet Pharmaceuticals (Bermuda)

US Patent
LigandPNGBDBM287676(US10085984, Example 54)
Affinity DataIC50: 100nMAssay Description:V79-4 cells expressing recombinant andrenodoxin and andrenodoxin reductase with either recombinant human CYP11B2 or CYP11B1 were prepared according t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/17/2019
Entry Details
Go to US Patent

TargetCytochrome P450 11B2, mitochondrial(Human)
Viamet Pharmaceuticals (Bermuda)

US Patent
LigandPNGBDBM287679(US10085984, Example 57 | US11040034, Ex. No. 57)
Affinity DataIC50: 100nMAssay Description:V79-4 cells expressing recombinant andrenodoxin and andrenodoxin reductase with either recombinant human CYP11B2 or CYP11B1 were prepared according t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/17/2019
Entry Details
Go to US Patent

TargetCytochrome P450 11B2, mitochondrial(Human)
Viamet Pharmaceuticals (Bermuda)

US Patent
LigandPNGBDBM287680(US10085984, Example 58 | US11040034, Ex. No. 58)
Affinity DataIC50: 100nMAssay Description:V79-4 cells expressing recombinant andrenodoxin and andrenodoxin reductase with either recombinant human CYP11B2 or CYP11B1 were prepared according t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/17/2019
Entry Details
Go to US Patent

TargetCytochrome P450 11B2, mitochondrial(Human)
Viamet Pharmaceuticals (Bermuda)

US Patent
LigandPNGBDBM287681(US10085984, Example 59 | US11040034, Ex. No. 59)
Affinity DataIC50: 100nMAssay Description:V79-4 cells expressing recombinant andrenodoxin and andrenodoxin reductase with either recombinant human CYP11B2 or CYP11B1 were prepared according t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/17/2019
Entry Details
Go to US Patent

TargetCytochrome P450 11B2, mitochondrial(Human)
Viamet Pharmaceuticals (Bermuda)

US Patent
LigandPNGBDBM287683(US10085984, Example 61 | US11040034, Ex. No. 61)
Affinity DataIC50: 100nMAssay Description:V79-4 cells expressing recombinant andrenodoxin and andrenodoxin reductase with either recombinant human CYP11B2 or CYP11B1 were prepared according t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/17/2019
Entry Details
Go to US Patent

TargetCytochrome P450 11B2, mitochondrial(Human)
Viamet Pharmaceuticals (Bermuda)

US Patent
LigandPNGBDBM287684(US10085984, Example 62 | US11040034, Ex. No. 62)
Affinity DataIC50: 100nMAssay Description:V79-4 cells expressing recombinant andrenodoxin and andrenodoxin reductase with either recombinant human CYP11B2 or CYP11B1 were prepared according t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/17/2019
Entry Details
Go to US Patent

TargetCytochrome P450 11B2, mitochondrial(Human)
Viamet Pharmaceuticals (Bermuda)

US Patent
LigandPNGBDBM287685(US10085984, Example 63 | US11040034, Ex. No. 63)
Affinity DataIC50: 100nMAssay Description:V79-4 cells expressing recombinant andrenodoxin and andrenodoxin reductase with either recombinant human CYP11B2 or CYP11B1 were prepared according t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/17/2019
Entry Details
Go to US Patent

TargetCytochrome P450 11B2, mitochondrial(Human)
Viamet Pharmaceuticals (Bermuda)

US Patent
LigandPNGBDBM287686(US10085984, Example 64 | US11040034, Ex. No. 64)
Affinity DataIC50: 100nMAssay Description:V79-4 cells expressing recombinant andrenodoxin and andrenodoxin reductase with either recombinant human CYP11B2 or CYP11B1 were prepared according t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/17/2019
Entry Details
Go to US Patent

TargetCytochrome P450 11B2, mitochondrial(Human)
Viamet Pharmaceuticals (Bermuda)

US Patent
LigandPNGBDBM287688(US10085984, Example 66 | US11040034, Ex. No. 66)
Affinity DataIC50: 100nMAssay Description:V79-4 cells expressing recombinant andrenodoxin and andrenodoxin reductase with either recombinant human CYP11B2 or CYP11B1 were prepared according t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/17/2019
Entry Details
Go to US Patent

Displayed 1 to 50 (of 272 total ) | Next | Last >>
Jump to: